Daily GLP-1 tablets are reshaping the race for the obesity market.
Drugmakers believe pills will attract new patients who avoid injections.
Analysts say the sector could reach $200bn within a decade.
Novo Nordisk launched the first oral Wegovy in the US in December.
Early demand has been strong, with tens of thousands of weekly prescriptions.
The treatment controls appetite in the same way as injectable drugs.
Patients are switching for practical and financial reasons.
Tablets cost less, need no refrigeration and are easier to take daily.
Some users report more stable hunger levels than with weekly shots.
Eli Lilly is preparing a rival pill, orforglipron, for launch.
Several biotech groups and AstraZeneca are developing similar therapies.
Falling prices and new insurance coverage will likely expand access.
Injections still produce greater weight loss in studies.
People with severe obesity may continue to use them.
Pills are expected to bring in patients who are overweight or mildly obese.
Global obesity is rising দ্রুত, and most eligible people remain untreated.
More formats and lower costs are turning weight-loss drugs into a mass market.
